SCI Abstract

search
+
HERTHENA-Lung02: phase III study of patritumab deruxtecan in advanced EGFR-mutated NSCLC after a third-generation EGFR TKI
HERTHENA-Lung02: phase III study of patritumab deruxtecan in advanced EGFR-mutated NSCLC after a third-generation EGFR TKI
After disease progression on EGFR tyrosine kinase inhibitor (TKI) therapy, patients with EGFR-mutated NSCLC who are then t...
CREST: phase III study of sasanlimab and Bacillus Calmette-Guérin for patients with Bacillus Calmette-Guérin-naïve high-risk non-muscle-invasive bladder cancer
CREST: phase III study of sasanlimab and Bacillus Calmette-Guérin for patients with Bacillus Calmette-Guérin-naïve high-risk non-muscle-invasive bladder cancer
Bacillus Calmette-Guérin (BCG) is the standard of care for patients with high-risk non-muscle-invasive bladder cancer (NMI...
INSURE: a pooled analysis of ixazomib-lenalidomide-dexamethasone for relapsed/refractory myeloma in routine practice
INSURE: a pooled analysis of ixazomib-lenalidomide-dexamethasone for relapsed/refractory myeloma in routine practice
Aim: We pooled data from three observational studies (INSIGHT MM, UVEA-IXA and REMIX) to investigate the real-world effect...
Brightline-2: a phase IIa/IIb trial of brigimadlin (BI 907828) in advanced biliary tract cancer, pancreatic ductal adenocarcinoma or other solid tumors
Brightline-2: a phase IIa/IIb trial of brigimadlin (BI 907828) in advanced biliary tract cancer, pancreatic ductal adenocarcinoma or other solid tumors
Mouse double minute 2 homolog (MDM2) is a key negative regulator of the tumor suppressor p53. Blocking the MDM2–p53 intera...
Development and validation of algorithms for identifying lines of therapy in multiple myeloma using real-world data
Development and validation of algorithms for identifying lines of therapy in multiple myeloma using real-world data
Aim: To validate algorithms based on electronic health data to identify composition of lines of therapy (LOT) in multiple ...
The value of the accelerated approval pathway: real-world outcomes associated with reducing the time between innovations
The value of the accelerated approval pathway: real-world outcomes associated with reducing the time between innovations
Aim: We investigated the effect of shortening time between innovations with the accelerated approval (AA) pathway on patie...
The phase I/II eNRGy trial: Zenocutuzumab in patients with cancers harboring NRG1 gene fusions
The phase I/II eNRGy trial: Zenocutuzumab in patients with cancers harboring NRG1 gene fusions
Neuregulin 1 (NRG1) fusions are oncogenic drivers that have been detected in non-small-cell lung cancer (NSCLC), pancreati...
Real-world treatment of metastatic hormone-sensitive prostate cancer in the USA, Europe and Asia
Real-world treatment of metastatic hormone-sensitive prostate cancer in the USA, Europe and Asia
Aim: To characterize real-world patients with metastatic hormone-sensitive prostate cancer (mHSPC) and treating physicians...
A plain language summary of the PHAROS study: the combination of encorafenib and binimetinib for people with BRAF V600E-mutant metastatic non-small cell lung cancer
A plain language summary of the PHAROS study: the combination of encorafenib and binimetinib for people with BRAF V600E-mutant metastatic non-small cell lung cancer
What is this summary about? This is a summary of the results of a study called PHAROS. This study looked at combination tr...
Measuring the composition of the tumor microenvironment with transcriptome analysis: past, present and future
Measuring the composition of the tumor microenvironment with transcriptome analysis: past, present and future
Interactions between tumor cells and immune cells in the tumor microenvironment (TME) play a vital role the mechanisms of ...
Real-world drug utilization and treatment patterns in patients with tenosynovial giant cell tumors in the USA
Real-world drug utilization and treatment patterns in patients with tenosynovial giant cell tumors in the USA
Aim: Real-world treatment patterns in tenosynovial giant cell tumor (TGCT) patients remain unknown. Pexidartinib is the on...
Selumetinib for children with neurofibromatosis type 1 and plexiform neurofibromas: A plain language summary of SPRINT
Selumetinib for children with neurofibromatosis type 1 and plexiform neurofibromas: A plain language summary of SPRINT
What is this summary about? This summary describes a publication about a study called SPRINT. The SPRINT study included 50...
Plain language summary of the CheckMate 76K study results: nivolumab given after stage 2B/2C melanoma is removed by surgery
Plain language summary of the CheckMate 76K study results: nivolumab given after stage 2B/2C melanoma is removed by surgery
What is this summary about? In this article, we summarize results from the ongoing phase 3 CheckMate 76K clinical study pu...
Elranatamab efficacy in MagnetisMM-3 compared with real-world control arms in triple-class refractory multiple myeloma
Elranatamab efficacy in MagnetisMM-3 compared with real-world control arms in triple-class refractory multiple myeloma
Elranatamab efficacy in the single-arm, registrational MagnetisMM-3 trial (NCT04649359) was compared with that of physicia...
An observational study of once-weekly carfilzomib in patients with multiple myeloma in Japan (Weekly-CAR study)
An observational study of once-weekly carfilzomib in patients with multiple myeloma in Japan (Weekly-CAR study)
Background: The ARROW study demonstrated that once-weekly carfilzomib and dexamethasone (wKd) therapy significantly prolon...
Design of a single-center, phase II trial to explore the efficacy and safety of ‘R-ISV-RO’ treatment in advanced tumors
Design of a single-center, phase II trial to explore the efficacy and safety of ‘R-ISV-RO’ treatment in advanced tumors
Background: The authors' preclinical study has confirmed that RO adjuvant (composed of TLR 7 agonists [imiquimod/R837] and...
Progression-free survival and safety at 3.5 years of follow-up: results from the randomized phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer – a plain language summary
Progression-free survival and safety at 3.5 years of follow-up: results from the randomized phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer – a plain language summary
What is this summary about? This PLSP provides a short summary of an original scientific article that presented results fr...
Prolonging the lives of African–Americans with metastatic breast cancer by adding palbociclib to an aromatase inhibitor in routine clinical practice: a plain language summary of a real-world database study
Prolonging the lives of African–Americans with metastatic breast cancer by adding palbociclib to an aromatase inhibitor in routine clinical practice: a plain language summary of a real-world database study
This summary is about a study that was published in the medical journal The Oncologist in July 2023. The combination of pa...
Treatment outcomes in older patients with metastatic breast cancer receiving palbociclib plus an aromatase inhibitor: a plain language summary
Treatment outcomes in older patients with metastatic breast cancer receiving palbociclib plus an aromatase inhibitor: a plain language summary
What is this summary about? This summary describes an article published in the medical journal Frontiers in Oncology in Se...
Plain language summary of the TRANSFORM study primary analysis results: liso-cell as a second treatment regimen for large B-cell lymphoma following failure of the first treatment regimen
Plain language summary of the TRANSFORM study primary analysis results: liso-cell as a second treatment regimen for large B-cell lymphoma following failure of the first treatment regimen
What is this summary about? People diagnosed with a disease called large B-cell lymphoma (LBCL) may experience return, or ...
format_indent_increase